Plasmatic level of neurosin predicts outcome of mild cognitive impairment
Authors:
- Manuel Menendez-GonzalezManuel Menendez-Gonzalez
- Patricia Castro-SantosPCPatricia Castro-Santos
- Maria T CalatayudMCMaria T Calatayud
- Pablo Perez-PiñeraPPPablo Perez-Piñera
- Renee RibacobaRRRenee Ribacoba
- Marta Martinez-RiveraMMMarta Martinez-Rivera
- Carmen GutierrezCGCarmen Gutierrez
- Alfonso Lopez-MuñizALAlfonso Lopez-Muñiz
- Ana SuarezASAna Suarez
Open Access
- 1 January 2008
- journal article
- Published by Springer Nature in International Archives of Medicine
- Vol. 1 (1) , 11
Abstract
Mild Cognitive Impairment (MCI) is a disorder considered to be a transitional stage from health to dementia. Diagnosis of dementias at these early stages is always troublesome because the pathophysiologic events leading to dementia precede clinical symptoms. Thus, the development of biomarkers that can be used to support the diagnosis of dementias at early stages is rapidly becoming a high priority. We have recently reported the value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease (AD). The aim of this study is to determine whether measuring plasmatic concentration of neurosin is a valuable test to predict progression of MCI.Keywords
This publication has 26 references indexed in Scilit:
- Proteinase-activated Receptors, Targets for Kallikrein SignalingJournal of Biological Chemistry, 2006
- Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCINeurology, 2006
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2005
- The Cardiovascular Actions of Protease-Activated ReceptorsMolecular Pharmacology, 2005
- Human Kallikrein 6 as a Biomarker of Alzheimer’s DiseaseClinical Biochemistry, 2000
- Localization of a novel type trypsin‐like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's diseasePsychiatry and Clinical Neurosciences, 2000
- Molecular Characterization of Zyme/Protease M/Neurosin (PRSS9), A Hormonally Regulated Kallikrein-like Serine ProteaseGenomics, 1999
- Vascular dementiaNeurology, 1993
- Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activationCell, 1991
- The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's diseaseNeurology, 1988